Annals of surgery
-
To define the relationship between the duration of smoking cessation and postoperative complications for patients with lung cancer undergoing surgical treatment. ⋯ Smoking cessation at least 3 weeks prior to the surgical treatment of lung cancer is associated with reduced morbidity and mortality. Providers should aggressively encourage smoking cessation in the preoperative period, since it can disproportionately impact outcomes in early-stage lung cancer.
-
To assess the effect of the Global Budget Revenue (GBR) program on outcomes after surgery. ⋯ Implementation of the GBR program is associated with improved outcomes and reductions in costs among Maryland patients who underwent surgical procedures. This is particularly salient given the increasing need to disseminate and scale population-based payment models that improve patient care while controlling health care costs.
-
The American Board of Surgery (ABS) sought to investigate the suitability of video-based assessment (VBA) as an adjunct to certification for assessing technical skills. ⋯ VBA is promising as an adjunct to the current board certification process and should be further considered by the ABS.
-
Randomized Controlled Trial
Professional Coaching and Surgeon Well-Being. A Randomized Controlled Trial.
To determine if individualized professional coaching reduces burnout, improves quality of life, and increases resilience among surgeons. ⋯ Professional coaching over 6 months improved burnout and resilience among surgeons, with reductions in improvement over the ensuing 6 months.
-
Randomized Controlled Trial Multicenter Study
Pelvic Intraoperative Neuromonitoring Prevents Dysfunction in Patients with Rectal Cancer: Results from a Multicenter, Randomized, Controlled Clinical Trial of a NEUROmonitoring System (NEUROS).
This NEUROmonitoring System (NEUROS) trial assessed whether pelvic intraoperative neuromonitoring (pIONM) could improve urogenital and ano-(neo-)rectal functional outcomes in patients who underwent total mesorectal excisions (TMEs) for rectal cancer. ⋯ pIONM is safe and has the potential to improve functional outcomes in rectal cancer patients undergoing TME.